Log in

NASDAQ:MGTX - MeiraGTx Stock Price, Forecast & News

$16.20
+0.43 (+2.73 %)
(As of 02/28/2020 04:00 PM ET)
Today's Range
$15.21
Now: $16.20
$16.48
50-Day Range
$15.77
MA: $18.92
$21.24
52-Week Range
$13.76
Now: $16.20
$30.23
Volume110,128 shs
Average Volume103,827 shs
Market Capitalization$592.43 million
P/E RatioN/A
Dividend YieldN/A
Beta2.24
MeiraGTx Holdings plc, a clinical-stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The company develops various therapies for ocular diseases, including rare inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; neurodegenerative diseases, such as amyothrophic lateral sclerosis; and Parkinson's diseases. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MGTX
CUSIPN/A
CIKN/A
Phone646-860-7985

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.96 per share

Profitability

Net Income$-82,870,000.00

Miscellaneous

Employees68
Market Cap$592.43 million
Next Earnings Date3/24/2020 (Estimated)
OptionableNot Optionable

Receive MGTX News and Ratings via Email

Sign-up to receive the latest news and ratings for MGTX and its competitors with MarketBeat's FREE daily newsletter.


MeiraGTx (NASDAQ:MGTX) Frequently Asked Questions

What is MeiraGTx's stock symbol?

MeiraGTx trades on the NASDAQ under the ticker symbol "MGTX."

How were MeiraGTx's earnings last quarter?

MeiraGTx Holdings PLC (NASDAQ:MGTX) released its quarterly earnings data on Thursday, November, 7th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.23. The company earned $3.58 million during the quarter. View MeiraGTx's Earnings History.

When is MeiraGTx's next earnings date?

MeiraGTx is scheduled to release their next quarterly earnings announcement on Tuesday, March 24th 2020. View Earnings Estimates for MeiraGTx.

What price target have analysts set for MGTX?

3 equities research analysts have issued twelve-month price objectives for MeiraGTx's shares. Their forecasts range from $30.00 to $45.00. On average, they anticipate MeiraGTx's stock price to reach $38.33 in the next twelve months. This suggests a possible upside of 136.6% from the stock's current price. View Analyst Price Targets for MeiraGTx.

What is the consensus analysts' recommendation for MeiraGTx?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MeiraGTx in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MeiraGTx.

What are Wall Street analysts saying about MeiraGTx stock?

Here are some recent quotes from research analysts about MeiraGTx stock:
  • 1. According to Zacks Investment Research, "MeiraGTx Holdings plc focuses on operating as a holding company for MeiraGTx Limited which operates as a clinical stage gene therapy company. It develops novel gene therapy treatments for inherited and acquired disorders. The company's product pipeline consists of AAV-CNGB3, AAV-CNGA3, AAV-RPE65, AAV-RPGR, AAV-AQP1, AAV-AQP1 and AAV-UPF1 which are in clinical stage. MeiraGTx Holdings plc is based in New York. " (1/8/2020)
  • 2. Chardan Capital analysts commented, "We rate MeiraGTx Buy on the forward- looking approach Meira management has taken to develop one of the broadest pipelines in all of AAV-based GT, including one with both lower-risk IRD opportunities for early wins and with higher-risk large-market opportunities that could generate profound investment returns." (9/23/2019)

Has MeiraGTx been receiving favorable news coverage?

News stories about MGTX stock have been trending very negative on Saturday, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. MeiraGTx earned a media sentiment score of -4.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the stock's share price in the near term. View News Stories for MeiraGTx.

Are investors shorting MeiraGTx?

MeiraGTx saw a drop in short interest in February. As of February 14th, there was short interest totalling 743,000 shares, a drop of 8.5% from the January 30th total of 812,400 shares. Based on an average daily trading volume, of 148,600 shares, the short-interest ratio is presently 5.0 days. Currently, 2.8% of the company's stock are short sold. View MeiraGTx's Current Options Chain.

Who are some of MeiraGTx's key competitors?

What other stocks do shareholders of MeiraGTx own?

Who are MeiraGTx's key executives?

MeiraGTx's management team includes the folowing people:
  • Dr. Alexandria Forbes, CEO, Pres & Director (Age 54)
  • Mr. Richard Brian Giroux, Chief Operating Officer (Age 46)
  • Dr. Stuart Naylor Ph.D., Chief Devel. Officer & Director (Age 56)
  • Ms. Katherine Edna Breedis C.F.A., CFA, CMT, Chief Financial Officer
  • Mr. Micah Zajic, VP of Corp. Devel.

When did MeiraGTx IPO?

(MGTX) raised $75 million in an IPO on Friday, June 8th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Barclays and Evercore ISI served as the underwriters for the IPO and Chardan was co-manager.

Who are MeiraGTx's major shareholders?

MeiraGTx's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include State Street Corp (0.93%), Alyeska Investment Group L.P. (0.91%), Rhenman & Partners Asset Management AB (0.52%), Geode Capital Management LLC (0.33%), Sectoral Asset Management Inc (0.26%) and Schonfeld Strategic Advisors LLC (0.24%). Company insiders that own MeiraGTx stock include Alexandria Forbes, Life Sciences Maste Perceptive, Nicole Seligman and Richard Giroux. View Institutional Ownership Trends for MeiraGTx.

Which institutional investors are selling MeiraGTx stock?

MGTX stock was sold by a variety of institutional investors in the last quarter, including Sectoral Asset Management Inc, Panagora Asset Management Inc., Alyeska Investment Group L.P., Renaissance Technologies LLC, Russell Investments Group Ltd., Goldman Sachs Group Inc. and Meeder Asset Management Inc.. Company insiders that have sold MeiraGTx company stock in the last year include Alexandria Forbes and Richard Giroux. View Insider Buying and Selling for MeiraGTx.

Which institutional investors are buying MeiraGTx stock?

MGTX stock was bought by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Parkman Healthcare Partners LLC, California Public Employees Retirement System, Acadian Asset Management LLC, Schonfeld Strategic Advisors LLC, Algert Global LLC, State Street Corp and Claraphi Advisory Network LLC. Company insiders that have bought MeiraGTx stock in the last two years include Life Sciences Maste Perceptive and Nicole Seligman. View Insider Buying and Selling for MeiraGTx.

How do I buy shares of MeiraGTx?

Shares of MGTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is MeiraGTx's stock price today?

One share of MGTX stock can currently be purchased for approximately $16.20.

How big of a company is MeiraGTx?

MeiraGTx has a market capitalization of $592.43 million. The company earns $-82,870,000.00 in net income (profit) each year or ($4.39) on an earnings per share basis. MeiraGTx employs 68 workers across the globe.View Additional Information About MeiraGTx.

What is MeiraGTx's official website?

The official website for MeiraGTx is http://www.meiragtx.com/.

How can I contact MeiraGTx?

MeiraGTx's mailing address is 450 East 29thStreet 15thFloor, NEW YORK NY, 10016. The company can be reached via phone at 646-860-7985 or via email at [email protected]


MarketBeat Community Rating for MeiraGTx (NASDAQ MGTX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  155 (Vote Outperform)
Underperform Votes:  110 (Vote Underperform)
Total Votes:  265
MarketBeat's community ratings are surveys of what our community members think about MeiraGTx and other stocks. Vote "Outperform" if you believe MGTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MGTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel